Home
About the PCRJ
Aims, Scope and History
Editorial Board
Online first
Current Issue
education@pcrj
Past Issues
Supplements
Translations
Most popular articles
Alerts
Subscribe
Instructions for Authors
Advertising
Disclaimer and Legal Notices
Contact Us
PDF View full text as PDF document

CrossRef Right click on this DOI link and copy link/shortcut to cite this article (What is a DOI link?)

Export Export to bibliographic software or plain text

CiteULike Post to CiteULike

Email this article Email this article to friend/s or colleague/s

Cited by Cited by
•   Back to table of contents

Volume 17 Issue 3 September 2008

Original Research

Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD

Pages 169-175
*Gunnar Johanssona, Anne Lindbergb, Kerstin Rombergc, Lars Nordströmd, Fronke Gerkene, Annika Roquetd

a Associate Professor, Nyby Healthcare Centre and Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden

b Senior Consultant, The OLIN Studies and Division of Respiratory Medicine, Sunderby Hospital, Luleå, Sweden

c General Practioner, Näset Healthcare Centre, Höllviken, Sweden

d Clinical monitor, Boehringer Ingelheim AB, Stockholm, Sweden

e Statistician, Boehringer Ingelheim Pharma GmbH & Co, Ingelheim, Germany

Received 21 December 2007 • Accepted 7 May 2008 • Online 6 June 2008


Abstract
AIMS: Evaluation of tiotropium efficacy in patients with mild chronic obstructive pulmonary disease (COPD) defined by the 2003 Swedish Society of Respiratory Medicine guidelines (post-bronchodilator FEV1/FVC <70%; FEV1 >60% predicted). METHODS: In this 12-week, randomised, double-blind, placebo-controlled study of tiotropium 18 mcg once daily versus placebo, respiratory function was assessed on Days 1, 15 and 85 (baseline: pre-dose Day 1). RESULTS: Mean±SD baseline FEV1 (% predicted) was 73.4±12.5 (tiotropium, n=107; placebo, n=117). Tiotropium significantly improved change from baseline in area under the curve from pre-dose to 2 hours post-dose (AUC0-2 h) FEV1 versus placebo, by 166±26 mL (mean±SE) at study end (p<0.0001). With tiotropium, there were significant increases in the change in AUC0-2 h FVC versus baseline, and trough FEV1 and FVC, versus placebo, on all test days (p<0.01). Adverse event rates were similar. CONCLUSION: Compared with placebo, tiotropium improved lung function in patients with mild COPD.

Cite as: Johansson G, Lindberg A, Romberg K, Nordstrom L, Gerken F, Roquet A. Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Prim Care Respir J 2008;17(3):169-175. DOI: http://dx.doi.org/10.3132/pcrj.2008.00037

Keywords
Chronic obstructive pulmonary disease, mild, moderate, tiotropium

* Corresponding author. Gunnar Johansson Tel: +46 18611 3427 Fax: +46 18511 657 Email: gunnar.johansson@pubcare.uu.se